Optimising the Role of "Herceptin" in Breast Cancer: Proceedings of a Symposium, Monte Carlo, June 19-21, 2000 (Oncology)
5 Angebote vergleichen
| Preise | Apr. 17 | Mai 17 | Juni 17 | Juli 17 | Aug. 17 |
|---|---|---|---|---|---|
| Schnitt | € 46,79 | € 52,28 | € 51,30 | € 27,23 | € 55,06 |
| Nachfrage |
1
Optimising the Role of Herceptin® in Breast Cancer (Supplement Issue: Oncology 2001, 2) (2001)
EN PB NW FEISBN: 9783805573276 bzw. 3805573278, Band: 61, in Englisch, 92 Seiten, S. Karger, Taschenbuch, neu, Erstausgabe.
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 24 hours, plus shipping (if shipped).
Von Händler/Antiquariat, Amazon.com.
Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy. Paperback, Edition: 1, Label: S. Karger, S. Karger, Product group: Book, Published: 2001-10-24, Studio: S. Karger, Sales rank: 17727796.
Von Händler/Antiquariat, Amazon.com.
Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy. Paperback, Edition: 1, Label: S. Karger, S. Karger, Product group: Book, Published: 2001-10-24, Studio: S. Karger, Sales rank: 17727796.
2
Optimising the Role of Herceptin® in Breast Cancer (Supplement Issue: Oncology 2001, 2) (2001)
EN PB NW FEISBN: 9783805573276 bzw. 3805573278, Band: 61, in Englisch, 92 Seiten, S. Karger, Taschenbuch, neu, Erstausgabe.
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 24 hours, plus shipping (if shipped).
Von Händler/Antiquariat, Amazon.com.
Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy. Paperback, Edition: 1, Label: S. Karger, S. Karger, Product group: Book, Published: 2001-10-24, Studio: S. Karger, Sales rank: 17877143.
Von Händler/Antiquariat, Amazon.com.
Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy. Paperback, Edition: 1, Label: S. Karger, S. Karger, Product group: Book, Published: 2001-10-24, Studio: S. Karger, Sales rank: 17877143.
3
Optimising the Role of Herceptin® in Breast Cancer (Supplement Issue: Oncology 2001, 2) (2001)
EN PB US FEISBN: 9783805573276 bzw. 3805573278, Band: 61, in Englisch, 92 Seiten, S. Karger, Taschenbuch, gebraucht, Erstausgabe.
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 1-2 business days.
Von Händler/Antiquariat, Red Rhino.
Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy. Paperback, Edition: 1, Label: S. Karger, S. Karger, Product group: Book, Published: 2001-10-24, Studio: S. Karger, Sales rank: 18134818.
Von Händler/Antiquariat, Red Rhino.
Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy. Paperback, Edition: 1, Label: S. Karger, S. Karger, Product group: Book, Published: 2001-10-24, Studio: S. Karger, Sales rank: 18134818.
4
Optimising the Role of Herceptin® in Breast Cancer (Supplement Issue: Oncology 2001, 2) (2001)
EN PB US FEISBN: 9783805573276 bzw. 3805573278, Band: 61, in Englisch, 92 Seiten, S. Karger, Taschenbuch, gebraucht, Erstausgabe.
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 1-2 business days.
Von Händler/Antiquariat, Red Rhino.
Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy. Paperback, Edition: 1, Label: S. Karger, S. Karger, Product group: Book, Published: 2001-10-24, Studio: S. Karger, Sales rank: 18369742.
Von Händler/Antiquariat, Red Rhino.
Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy. Paperback, Edition: 1, Label: S. Karger, S. Karger, Product group: Book, Published: 2001-10-24, Studio: S. Karger, Sales rank: 18369742.
5
Symbolbild
Optimising the Role of "Herceptin" in Breast Cancer
EN PB NWISBN: 9783805573276 bzw. 3805573278, in Englisch, S Karger Ag, Taschenbuch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…